TABLE 1.
MIC distributions of cefepime/zidebactam and other antibiotics for major resistance groupsa
| Organism group | Number of P. aeruginosa isolates with indicated MIC (mg/L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≤ 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | ≥128 | |
| KPC producers (n = 19) | ||||||||||
| Cefepime | 19 | |||||||||
| Cefepime/zidebactam | 6 | 8 | 2 | 3 | ||||||
| Cefepime/taniborbactam | 1 | 2 | 7 | 1 | 8 | |||||
| Ceftolozane/tazobactam | 3 | 1 | 4 | 5 | 6 | |||||
| Ceftazidime/avibactam | 1 | 4 | 2 | 6 | 3 | 2 | 1 | |||
| Aztreonam/avibactam | 6 | 9 | 3 | 1 | ||||||
| Imipenem/relebactam | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 1 | 4 | |
| Meropenem | 1 | 2 | 16 | |||||||
| Meropenem/vaborbactam | 2 | 1 | 2 | 3 | 11 | |||||
| MBL producers (n = 18) | ||||||||||
| Cefepime | 2 | 3 | 3 | 10 | ||||||
| Cefepime/zidebactam | 3 | 7 | 5 | 2 | 1 | |||||
| Cefepime/taniborbactam | 2 | 3 | 1 | 6 | 6 | |||||
| Ceftolozane/tazobactam | 18 | |||||||||
| Ceftazidime/avibactam | 4 | 5 | 9 | |||||||
| Aztreonam/avibactam | 1 | 1 | 6 | 3 | 2 | 4 | 1 | |||
| Imipenem/relebactam | 1 | 1 | 4 | 12 | ||||||
| Meropenem | 2 | 3 | 1 | 5 | 7 | |||||
| Meropenem/vaborbactam | 1 | 2 | 4 | 5 | 4 | 2 | ||||
| Non-carbapenemase producers (n = 71) | ||||||||||
| Cefepime | 2 | 2 | 10 | 14 | 10 | 11 | 12 | 10 | ||
| Cefepime/zidebactam | 1 | 1 | 14 | 23 | 25 | 4 | 3 | |||
| Cefepime/taniborbactam | 3 | 6 | 15 | 15 | 11 | 6 | 4 | 11 | ||
| Ceftolozane/tazobactam | 4 | 14 | 9 | 8 | 7 | 5 | 3 | 1 | 7 | 13 |
| Ceftazidime/avibactam | 1 | 5 | 7 | 8 | 14 | 11 | 2 | 7 | 16 | |
| Aztreonam/avibactam | 5 | 6 | 8 | 22 | 15 | 15 | ||||
| Imipenem/relebactam | 4 | 2 | 13 | 25 | 18 | 8 | 1 | |||
| Meropenem | 2 | 4 | 10 | 11 | 18 | 16 | 7 | 3 | ||
| Meropenem/vaborbactam | 1 | 3 | 4 | 10 | 13 | 25 | 9 | 4 | 2 | |
a
Susceptible range (FDA criteria) for each agent except for cefepime/zidebactam, cefepime/taniborbactam, aztreonam/avibactam and meropenem/vaborbactam is depicted by boldfaced numbers; for these approved antibiotics, FDA breakpoints are consistent with CLSI breakpoints. MIC of cefepime/zidebactam was determined at 1:1 ratio. A fixed 4 mg/L of inhibitor concentration was used for cefepime/taniborbactam, ceftolozane/tazobactam, ceftazidime/avibactam, and imipenem/relebactam. A fixed 8 mg/L of inhibitor concentration was used for meropenem/vaborbactam.